- Home
- CRON vs ABVX Comparison
CRON vs ABVX Comparison
Compare CRON & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRON
- ABVX
- Stock Information
- Founded
- CRON 2012
- ABVX 2013
- Country
- CRON Canada
- ABVX France
- Employees
- CRON N/A
- ABVX N/A
- Industry
- CRON Medicinal Chemicals and Botanical Products
- ABVX
- Sector
- CRON Health Care
- ABVX
- Exchange
- CRON Nasdaq
- ABVX Nasdaq
- Market Cap
- CRON 737.8M
- ABVX 722.3M
- IPO Year
- CRON N/A
- ABVX N/A
- Fundamental
- Price
- CRON $1.99
- ABVX $6.16
- Analyst Decision
- CRON Hold
- ABVX Strong Buy
- Analyst Count
- CRON 2
- ABVX 7
- Target Price
- CRON $3.00
- ABVX $37.86
- AVG Volume (30 Days)
- CRON 1.5M
- ABVX 216.6K
- Earning Date
- CRON 02-27-2025
- ABVX 09-09-2024
- Dividend Yield
- CRON N/A
- ABVX N/A
- EPS Growth
- CRON N/A
- ABVX N/A
- EPS
- CRON N/A
- ABVX N/A
- Revenue
- CRON $111,229,000.00
- ABVX $9,676,417.00
- Revenue This Year
- CRON $40.73
- ABVX $31.67
- Revenue Next Year
- CRON $18.84
- ABVX $759.77
- P/E Ratio
- CRON N/A
- ABVX N/A
- Revenue Growth
- CRON 30.31
- ABVX 100.87
- 52 Week Low
- CRON $1.86
- ABVX $5.54
- 52 Week High
- CRON $3.14
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- CRON 48.78
- ABVX 30.30
- Support Level
- CRON $1.93
- ABVX $5.54
- Resistance Level
- CRON $2.01
- ABVX $6.46
- Average True Range (ATR)
- CRON 0.07
- ABVX 0.51
- MACD
- CRON 0.00
- ABVX -0.04
- Stochastic Oscillator
- CRON 34.83
- ABVX 30.10
About CRON Cronos Group Inc. Common Share
Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.